fda tirzepatide osa Eli Lilly's Zepbound Becomes First FDA-Approved Drug Therapy for Sleep Apnea FDA approves weight-loss drug Zepbound

There were infrequent reports of life-threatening anaphylaxis requiring emergent medical attention

Strongest Current Evidence CagriSema REDEFINE 1 and REDEFINE 2 are completed phase 3 trials published in NEJM with over 4,600 participants

in relation to their weight-loss and diabetes medications: Ozempic (semaglutide) [2018] Rybelsus (semaglutide) [2020] Wegovy (semaglutide) [2021] Mounjaro (tirzepatide) [2022] Trulicity (dulaglutide) [2022] Saxenda (liraglutide) [2015] Victoza (tirzepatide) [2010] The proposed class action is based on allegations that these drugs have improperly disclosed or failed to warn about certain side effects such as: - Gastroparesis / stomach paralysis - Gastric statis - Ileus - Gastric obstruction - Intestinal obstruction These medical conditions often lead to hospitalization, surgery, and vomiting for extended lengths of time

Which biomarkers does the post say give context for how someone is responding at a given dose